REG - hVIVO plc - Director's Dealings

hVIVOAnnouncement

10/08/2018 07:05

RNS Number : 4047X
hVIVO plc
10 August 2018
 


 
hVIVO PLC
("hVIVO" or the "Company")
 
Director's Dealings
 
London, UK, 10 August 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, was notified yesterday that on 9 August 2018, Dr Trevor Phillips, Executive Chairman of the Company, purchased 23,500 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 65.0 pence per share.
 
Following this transaction, Dr Phillips' total interest in the Company has increased by 23,500 Ordinary Shares to a total of 32,535 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital.
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
 




1


Details of the persons discharging managerial responsibilities/persons closely associated




a)


Name


Dr Trevor Phillips




2


Reason for the notification




a)


Position/ status


Executive Chairman




b)


Initial notification/ Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


hVIVO plc




b)


Legal Entity Identifier


N/A




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary shares of 5 pence each
 
 
 GB00B6ZM0X53




b)


Nature of the transaction


Acquisition of ordinary shares




c)


Currency


GBP




d)


Price(s) and volume(s)






Director


Price (p)


Volume




Dr Trevor Phillips


65.0


23,500




 




 




e)


Aggregated information
- Aggregated volume
- Price
- Aggregated total


 
 
23,500


65.0p
£15,275.00
 




f)


Date of the transaction


9 August 2018




g)


Place of the transaction


London Stock Exchange, AIM




 
For further information please contact:
 




hVIVO plc


 




Trevor Phillips (Executive Chairman)


+44 207 756 1300




Fleur Wood (Director, Investor Relations)
 


 




Numis Securities Limited


 +44 207 260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)


 




James Black / Michael Burke (Corporate Broking)


 




 


 




FTI Consulting


 




Simon Conway / Victoria Foster Mitchell


+44 203 727 1000




 
 
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUGUBURUPRPGB